Currently, tumor intrinsic features, such as tumor PD-L1 immunohistochemistry (IHC) and tumor mutational burden (TMB), are the most studied biomarkers for the prediction of response to ICB in NSCLC. The gene discussed is CD274; the disease is neoplasm.